ICD10 code of Proteus syndrome and ICD9 code

Proteus syndrome is classified under the ICD-10 code Q87.3 (Congenital malformation syndromes involving overgrowth) and was previously identified in ICD-9 under the code 759.89 (Other specified congenital anomalies). Because Proteus syndrome is an extremely rare, mosaic disorder characterized by progressive, asymmetric overgrowth of various tissues, these codes are used for administrative and diagnostic tracking within healthcare systems.

What is the clinical nature of Proteus syndrome?

Proteus syndrome is a complex, sporadic condition caused by a post-zygotic somatic activating mutation in the AKT1 gene. Unlike hereditary conditions, Proteus syndrome is not passed from parent to child; it occurs randomly after conception, meaning only certain cells in the body carry the mutation. This mosaicism explains why the severity and location of overgrowth can vary so significantly from one person to another. Within the DiseaseMaps community, we have seen firsthand how the unpredictable nature of Proteus syndrome impacts daily life, as it often presents with localized gigantism, abnormal adipose tissue distribution, and specific vascular malformations.

How is Proteus syndrome diagnosed?

Diagnosis of Proteus syndrome is primarily clinical, guided by the Biesecker diagnostic criteria. Because the disease is so rare—with fewer than 1,000 cases documented in medical literature worldwide—it is often misdiagnosed as other overgrowth syndromes. To confirm a diagnosis of Proteus syndrome, clinicians typically evaluate the following:

• Mosaic distribution: The lesions must be patchy or asymmetric in their distribution.


• Progressive course: The overgrowth typically worsens over time rather than remaining static.


• Specific tissue involvement: Evidence of cerebriform connective tissue nevi (CCTN), disproportionate overgrowth of limbs, skull, or viscera, and vascular malformations.


• Genetic confirmation: While the diagnosis is clinical, identifying the specific AKT1 mutation in affected tissue samples provides definitive molecular confirmation.

What are the emotional and psychological challenges?

Living with Proteus syndrome involves navigating not only physical challenges but also significant psychological stressors. Patients often face social stigma due to visible physical differences, which can lead to isolation. At DiseaseMaps.org, 5 individuals have shared their experiences, highlighting the importance of connecting with others who understand the rare, non-inherited nature of the condition. Support from clinical psychologists who specialize in visible differences can be vital in building resilience and managing the anxiety associated with the unpredictable progression of Proteus syndrome symptoms.

Are there specialized treatments available?

Currently, there is no cure for Proteus syndrome, and management is strictly multidisciplinary. Treatment focuses on monitoring complications such as deep vein thrombosis (DVT) and pulmonary embolism, which are higher risks for these patients. Surgical intervention, such as orthopedic procedures for limb length discrepancy, is sometimes considered, but must be approached with caution due to the risk of abnormal tissue regrowth. Emerging research into AKT-inhibitors is an area of active clinical interest, though these therapies are still being evaluated for safety and efficacy in the context of Proteus syndrome.

Next steps

• Consult with a geneticist or a specialist in pediatric or adult medical genetics to discuss clinical diagnostic criteria.


• Maintain regular screening with a vascular specialist, as vascular malformations in Proteus syndrome can lead to life-threatening clotting issues.


• Join the DiseaseMaps community to connect with other patients and families navigating the complexities of this rare diagnosis.


• Monitor for clinical trials through the NIH or specialized rare disease research centers that specifically target PIK3CA-related or AKT-related overgrowth disorders.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Proteus Syndrome.


• Orphanet: Rare Disease Database (ORPHA: 745).


• OMIM (Online Mendelian Inheritance in Man): Proteus Syndrome (#176920).


• The Proteus Syndrome Foundation: Patient advocacy and clinical resources.